US Patients Staying on Wegovy for About 6 Months

Published on August 7, 2024

U.S. patients are on average staying on Novo Nordisk’s (NOVOb.CO) Wegovy weight-loss medication for just six months, an executive said on Wednesday, attributing the short time to the low availability of the wildly popular drug. Doug Langa, Novo’s head of North America…

Read Full Article (External Site)